Biosimulation assays, computer-aided mathematical simulations of biological processes, are integral to our predictive medicine platform. This advanced technology simplifies complex biological systems into manageable models, allowing for model-based predictions of how cells or organs respond to chemicals.
Unlike traditional methods relying on next-generation sequencing (NGS) that take weeks to yield results, biosimulation assays can provide predictive insights in just a few days. By using flow cytometry to analyze patient samples, these assays bypass the need for specific genetic mutations or molecular markers. Instead, they focus on the biological behavior of cancer cells in response to various drugs, offering highly individualized predictions of treatment efficacy and ensuring that patients receive the most effective therapies promptly.
The importance of biosimulation assays in the Notable platform lies in their ability to quickly personalize cancer treatment. In conditions like acute myeloid leukemia (AML), timely treatment decisions are critical, and delays can significantly impact patient outcomes. By enabling model-based predictions within the standard diagnostic timeframe, biosimulation assays optimize patient care and reduce the risk of adverse effects from ineffective therapies. The quality of these predictions depends on the quality of the models, which are defined by robust data and profound biological knowledge. By leveraging high-quality biosimulation models, Notable can provide a tailored, data-driven approach to cancer treatment, improving survival rates and quality of life for patients.
